What Is CAR T-Cell Therapy for Mesothelioma?

How CAR T-Cell Therapy Works

Chimeric Antigen Receptor (CAR) T-cell therapy is a form of cellular immunotherapy that harnesses the patient's own immune system to fight cancer. The process begins with leukapheresis — collecting T-cells (a type of white blood cell) from the patient's blood. These T-cells are then sent to a laboratory where they are genetically engineered to express a chimeric antigen receptor, a synthetic protein designed to recognize a specific target on cancer cells.

For mesothelioma, most CAR T-cell programs target mesothelin, a protein that is highly expressed on mesothelioma cells but has limited presence on normal tissues. According to the National Cancer Institute, once the CAR T-cells are engineered, they are multiplied in the laboratory to produce millions of copies, then infused back into the patient where they seek out and destroy cancer cells bearing the target protein.

Current Research in Mesothelioma

Several institutions are conducting CAR T-cell trials for mesothelioma. Memorial Sloan Kettering Cancer Center has been a leader in this research, testing mesothelin-targeted CAR T-cells delivered directly into the pleural space (the area around the lungs where pleural mesothelioma grows). This regional delivery approach aims to concentrate the engineered cells at the tumor site for maximum effect.

Other research groups are testing CAR T-cells delivered intravenously, which allows the cells to circulate throughout the body and potentially address disease that has spread beyond the pleural cavity. Next-generation CAR T-cell designs incorporate additional genetic modifications to improve persistence, reduce exhaustion, and overcome the immunosuppressive environment that mesothelioma tumors create.

Potential Benefits and Risks

CAR T-cell therapy has shown remarkable success in certain blood cancers, and researchers are working to translate that success to solid tumors like mesothelioma. Early-phase trials in mesothelioma have demonstrated that CAR T-cells can reach the tumor, persist in the body, and in some cases produce measurable tumor responses. The approach offers the potential for a highly targeted, personalized treatment.

Risks include cytokine release syndrome (CRS), a potentially serious inflammatory reaction that occurs when CAR T-cells activate in large numbers. Neurotoxicity is another possible side effect. Both complications are manageable in specialized treatment centers experienced with CAR T-cell therapy, but they require close monitoring and sometimes intensive care.

Accessing CAR T-Cell Trials

CAR T-cell trials for mesothelioma are available at select academic medical centers. Check ClinicalTrials.gov for currently recruiting trials and discuss this option with your oncologist. Eligibility criteria vary but typically require confirmed mesothelioma, adequate organ function, and often prior treatment with standard chemotherapy.

Pursuing legal compensation for asbestos exposure can help cover travel and lodging costs associated with accessing these specialized trials, which are currently available at only a limited number of institutions.